Tumor shedding of laminin binding protein modulates angiostatin production in vitro and interferes with plasmin-derived inhibition of angiogenesis in aortic ring cultures

International Journal of Cancer

Volumn 118, Issue 10, 2006, Pages 2421-2432

  Moss, Britney L ^a   Taubner, Lara ^a   Sample, Yekaterina K ^a   Kazmin, Dmitri A ^a   Copié, Valérie ^a   Starkey, Jean R ^a  

^a MONTANA STATE UNIVERSITY   (United States)

Author keywords

Angiogenesis; Angiostatin; Laminin binding protein; Limited proteolysis

Indexed keywords

ANGIOSTATIN; LAMININ 1; LAMININ BINDING PROTEIN; PLASMIN; THIOL OXIDASE;

AMINO ACID SEQUENCE; ANGIOGENESIS; ANIMAL CELL; ANTIANGIOGENIC ACTIVITY; ARTICLE; BINDING COMPETITION; CATALYSIS; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FOLDING; PROTEIN PROTEIN INTERACTION; SOLID TUMOR; TUMOR CELL; TUMOR GROWTH; VASCULAR RING;

ANIMALS; AORTA; LAMININ; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PLASMIN; PROTEIN BINDING; RATS; RECEPTORS, LAMININ;

EID: 33646387454     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21674     Document Type: Article

References (86)

1. Mafune K, Ravikumar TS, Wong JM, Yow H, Chen LB, Steele GD, Jr. Expression of a MW 32,000 Laminin-binding protein messenger RNA in human colon carcinoma correlates with disease progression. Cancer Res 1990;50:3888-91.
2. Castronovo V. Laminin receptors and laminin-binding proteins during tumor invasion and metastasis. Invasion Metastasis 1993;13:1-30.
3. Wewer UM, Liotta LA, Jaye M, Ricca GA, Drohan WN, Claysmith AP, Rao CN, Wirth P, Coligan JE, Albrechtsen R, Mudry M, Sobel ME. Altered levels of laminin receptor mRNA in various human carcinoma cells that have different abilities to bind laminin. Proc Natl Acad Sci USA 1986;83:7137-41.
4. Clausse N, Jackers P, Castronovo V. The 37 LRP/p40 polypeptide: a multifunctional pleiotropic molecule involved in tumorigenesis and metastasis-a review. Belg J Zool 1997;127:3-11.
5. Lee WA, Kim WH, Kim YI, Yang HK, Kim JP, Kleinman HK. Overexpression of the 67 kD laminin receptor correlates with the progression of gastric carcinoma. Pathol Res Pract 1996;192:1195-201.
6. Martignone S, Menard S, Bufalino R, Cascinelli N, Pellegrini R, Tagliabue E, Andreola S, Rilke F, Colnaghi MI. Prognostic significance of the 67-kilodalton laminin receptor expression in human breast carcinomas. J Natl Cancer Inst 1993;85:398-402.
7. Ménard S, Tagliabue E, Colnaghi MI. The 67 kDa laminin receptor as a prognostic factor in human cancer. Breast Cancer Res Treat 1998;52:137-45.
8. Waltregny D, De Leval L, Coppens L, Youssef E, De Leval J, Castronovo V. Detection of the 67-kD laminin receptor in prostate cancer biopsies as a predictor of recurrence after radical prostatectomy. Eur Urol 2001;40:495-503.
9. Ding SJ, Li Y, Shao XX, Zhou H, Zeng R, Tang ZY, Xia QC. Proteome analysis of hepatocellular carcinoma cell strains, MHCC97-H and MHCC97-L, with different metastasis potentials. Proteomics 2004;4:982-94.
10. Vigneswaran N, Wu J, Sacks P, Gilcrease M, Zacharias W. Microarray gene expression profiling of cell lines from primary and metastatic tongue squamous cell carcinoma: possible insights from emerging technology. J Oral Pathol Med 2005;34:77-86.
11. Vacca A, Ribatti D, Roncali L, Lospalluti M, Serio G, Carrel S, Dammacco F. Melanocyte tumor progression is associated with changes in angiogenesis and expression of the 67-kilodalton laminin receptor. Cancer 1993;72:455-61.
12. Stitt AW, McKenna D, Simpson DAC, Gardiner TA, Harriott P, Archer DB, Nelson J. The 67-kd laminin receptor is preferentially expressed by proliferating retinal vessels in a murine model of ischemic retinopathy. Am J Pathol 1998;152:1359-65.
13. Starkey JR, Uthayakumar S, Berglund DL. Cell surface and substrate distribution of the 67-kDa laminin binding protein determined by using a ligand photoaffinity probe. Cytometry 1999;35:37-47.
14. Karpatová M, Tagliabue E, Castronovo V, Magnifico A, Ardini E, Morelli D, Belotti D, Colnaghi MI, Ménard S. Shedding of the 67-kD laminin receptor by human cancer cells. J Cell Biochem 1996;60:226-34.
15. Ardini E, Sporchia B, Pollegioni L, Modugno M, Ghirelli C, Castiglioni F, Tagliabue E, Menard S. Identification of a novel function for 67-kDa laminin receptor: increase in laminin degradation rate and release of motility fragments. Cancer Res 2002;62:1321-5.
16. Magnifico A, Tagliabue E, Butó S, Ardini E, Castronovo V, Colnaghi MI, Ménard S. Peptide G, containing the binding site of the 67-kDa laminin receptor, increases and stabilizes laminin binding to cancer cells. J Biol Chem 1996;271:31179-84.
17. Bemo V, Porrini D, Castiglioni F, Campiglio M, Casalini P, Pupa SM, Balsari A, Menard S, Tagliabue E. The 67 kDa laminin receptor increases tumor aggressiveness by remodeling laminin-1. Endocr Relat Cancer 2005;12:393-406.
18. Neal MS. Angiogenesis: is it the key to controlling the healing process? J Wound Care 2001;10:281-7.
19. Twining SS, Wilson PM, Ngamkitidechakul C. Extrahepatic synthesis of plasminogen in the human comea is up-regulated by interleukins-1α and -1β. Biochem J 1999;339(Pt 3):705-12.
20. Stathakis P, Fitzgerald M, Matthias LJ, Chesterman CN, Hogg PJ. Generation of angiostatin by reduction and proteolysis of plasmin. Catalysis by a plasmin reductase secreted by cultured cells. J Biol Chem 1997;272:20641-5.
21. Stathakis P, Lay AJ, Fitzgerald M, Schlieker C, Matthias LJ, Hogg PJ. Angiostatin formation involves disulfide bond reduction and proteolysis in kringle 5 of plasmin. J Biol Chem 1999;274:8910-6.
22. Lay AJ, Jiang XM, Kisker O, Flynn E, Underwood A, Condron R, Hogg PJ. Phosphoglycerate kinase acts in tumour angiogenesis as a disulphide reductase. Nature 2000;408:869-73.
23. Kassam G, Kwon M, Yoon CS, Graham KS, Young MK, Gluck S, Waisman DM. Purification and characterization of A61. An angiostatin-like plasminogen fragment produced by plasmin autodigestion in the absence of sulfhydryl donors. J Biol Chem 2001;276:8924-33.
24. Yow H, Wong JM, Chen HS, Lee C, Steele GD, Jr, Chen LB. Increased mRNA expression of a laminin-binding protein in human colon carcinoma: complete sequence of a full-length cDNA encoding the protein. Proc Natl Acad Sci USA 1988;85:6394-8.
25. Satoh K, Narumi K, Sakai T, Abe T, Kikuchi T, Matsushima K, Sindoh S, Motomiya M. Cloning of 67-kDa laminin receptor cDNA and gene expression in normal and malignant cell lines of the human lung. Cancer Lett 1992;62:199-203.
26. Buto S, Tagliabue E, Ardini E, Magnifico A, Ghirelli C, van den BF, Castronovo V, Colnaghi MI, Sobel ME, Menard S. Formation of the 67-kDa laminin receptor by acylation of the precursor. J Cell Biochem 1998;69:244-51.
27. Landowski TH, Selvanayagam U, Starkey JR. Control pathways of the 67 kDa laminin binding protein: surface expression and activity of a new ligand binding domain. Clin Exp Metastasis 1995;13:357-72.
28. Kazmin DA, Hoyt TR, Taubner L, Teintze M, Starkey JR. Phage display mapping for peptide 11 sensitive sequences binding to laminin-1. J Mol Biol 2000;298:431-45.
29. Castronovo V, Taraboletti G, Sobel ME. Synthetic peptide to laminin receptor inhibits cancer cells attachment to endothelium. Clin Exp Metastasis 1990;8:99.
30. Iwamoto Y, Graf J, Sasaki M, Kleinman HK, Greatorex D, Martin GR, Robey FA, Yamada Y. Synthetic pentapeptide from the B1 chain of laminin promotes B16F10 melanoma cell migration. J Cell Phys 1988;134:287-91.
31. Iwamoto Y, Robey FA, Graf J, Sasaki M, Kleinman HK, Yamada Y, Martin GR. YIGSR, a synthetic laminin pentapeptide, inhibits experimental metastasis formation. Science 1987;238:1132-4.
32. Koliakos KK, Sapountzi Z, Papageorgiou A, Trachana V, Kotsinou S, Koliakos G. Antiidiotypic antibodies carrying the "internal image" of peptide YIGSR inhibit spontaneous metastasis of Lewis lung carcinoma in mice. In Vivo 2002;16:511-8.
33. Sakamoto N, Iwahana M, Tanaka NG, Osada Y. Inhibition of angiogenesis and tumor growth by a synthetic laminin peptide, CDPG-YIGSR-NH2. Cancer Res 1991;51:903-6.
34. Castronovo V, Taraboletti G, Sobel ME. Laminin receptor complementary DNA-deduced synthetic peptide inhibits cancer cell attachment to endothelium. Cancer Res 1991;51:5672-8.
35. Guo N, Krutzsch HC, Vogel T, Roberts DD. Interactions of a laminin-binding peptide from a 33-kDa protein related to the 67-kDa laminin receptor with laminin and melanoma cells are heparin-dependent. J Biol Chem 1992;267:17743-7.
36. Ardini E, Pesole G, Tagliabue E, Magnifico A, Castronovo V, Sobel ME, Colnaghi MI, Ménard S. The 67-kDa laminin receptor originated from a ribosomal protein that acquired a dual function during evolution. Mol Biol Evol 1998;15:1017-25.
37. Wang K-S, Kuhn RJ, Strauss EG, Ou S, Strauss JH. High-affinity laminin receptor is a receptor for Sindbis virus in mammalian cells. J Virol 1992;66:4992-5001.
38. Landowski TH, Dratz EA, Starkey JR. Studies of the structure of the metastasis associated 67 kDa laminin binding protein: fatty acid acylation and evidence supporting dimerization of the 32 kDa gene product to form the mature protein. Biochemistry 1995;34:11276-87.
39. Crook EM, Mathias AP, Rabin BR. Spectrophotometric assay of bovine pancreatic ribonuclease by the use of cytidine 2′:3′-phosphate. Biochem J 1960;4:234-8.
40. Crook EM, Mathias AP, Rabin BR. The preparation and purification of cytidine 2′:3′-phosphate. Biochem J 1960;74:230-3.
41. Lyles MM, Gilbert HF. Catalysis of the oxidative folding of ribonuclease A by protein disulfide isomerase: pre-steady-state kinetics and the utilization of the oxidizing equivalents of the isomerase. Biochemistry 1991;30:619-25.
42. Lyles MM, Gilbert HF. Catalysis of the oxidative folding of ribonuclease A by protein disulfide isomerase: dependence of the rate on the composition of the redox buffer. Biochemistry 1991;30:613-9.
43. Holmgren A. Thioredoxin catalyzes the reduction of insulin disulfides by dithiothreitol and dihydrolipoamide. J Biol Chem 1979;254:9627-32.
44. Holmgren A. Reduction of disulfides by thioredoxin. Exceptional reactivity of insulin and suggested functions of thioredoxin in mechanism of hormone action. J Biol Chem 1979;254:9113-9.
45. Robertson NP, Starkey JR, Hamner S, Meadows GG. Tumor cell invasion of three-dimensional matrices of defined composition: evidence for a specific role for heparan sulfate in rodent cell lines. Cancer Res 1989;49:1816-23.
46. Seglen PO. Preparation of rat liver cells. 3. Enzymatic requirements for tissue dispersion. Exp Cell Res 1973;82:391-8.
47. Seglen PO. Preparation of isolated rat liver cells. Methods Cell Biol 1976;13:29-83.
48. Carey J. A systematic and general proteolytic method for defining structural and functional domains of proteins. Methods Enzymol 2000;328:499-514.
49. Thormahlen M, Marx A, Muller SA, Song Y, Mandelkow EM, Aebi U, Mandelkow E. Interaction of monomeric and dimeric kinesin with microtubules. J Mol Biol 1998;275:795-809.
50. Sorokin AV, Mikhailov AM, Kachko AV, Protopopova EV, Konovalova SN, Andrianova ME, Netesov SV, Kornev AN, Loktev VB. Human recombinant laminin-binding protein: isolation, purification, and crystallization. Biochemistry (Mosc) 2000;65:546-53.
51. Chebotareva NA, Kurganov BI, Livanova NB. Biochemical effects of molecular crowding. Biochemistry (Mosc) 2004;69:1239-51.
52. Martens E, Alloza I, Scott CJ, Billiau A, Vandenbroeck K. Protein disulfide isomerase-mediated cell-free assembly of recombinant interleukin-12 p40 homodimers. Eur J Biochem 2000;267:6679-83.
53. Du C, Wolfe JL. Kinetic study of recombinant human protein disulphide isomerase-assisted C125A recombinant human interleukin-2 folding. Biotechnol Appl Biochem 2003;37:129-38.
54. Gately S, Twardowski P, Stack MS, Cundiff DL, Grella D, Castellino FJ, Enghild J, Kwaan HC, Lee F, Kramer RA, Volpert O, Bouck N, Soff GA. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc Natl Acad Sci USA 1997;94:10868-72.
55. Grosso LE, Park PW, Mecham RP. Characterization of a putative clone for the 67-kilodalton elastin/laminin receptor suggests that it encodes a cytoplasmic protein rather than a cell surface receptor. Biochemistry 1991;30:3346-50.
56. Magnifico A, Tagliabue E, Buto S, Ardini E, Castronovo V, Colnaghi MI, Menard S. Peptide G, containing the binding site of the 67-kDa laminin receptor, increases and stabilizes laminin binding to cancer cells. J Biol Chem 1996;271:31179-84.
57. Starkey JR, Dai S, Dratz EA. Sidechain and backbone requirements for anti-invasive activity of laminin peptide 11. Biochim Biophys Acta Protein Struct Mol Enzymol 1998;1429:187-207.
58. Menard S, Castronovo V, Tagliabue E, Sobel ME. New insights into the metastasis-associated 67 kD laminin receptor. J Cell Biochem 1997;67:155-65.
59. Lay AJ, Jiang XM, Daly E, Sun L, Hogg PJ. Plasmin reduction by phosphoglycerate kinase is a thiol-independent process. J Biol Chem 2002;277:9062-8.
60. Stallcup WB. The NG2 proteoglycan: past insights and future prospects. J Neurocytol 2002;31:423-35.
61. Goretzki L, Lombardo CR, Stallcup WB. Binding of the NG2 proteoglycan to kringle domains modulates the functional properties of angiostatin and plasmin(ogen). J Biol Chem 2000;275:28625-33.
62. Ozerdem U, Monosov E, Stallcup WB. NG2 proteoglycan expression by pericytes in pathological microvasculature. Microvasc Res 2002;63:129-34.
63. Burg MA, Grako KA, Stallcup WB. Expression of the NG2 proteoglycan enhances the growth and metastatic properties of melanoma cells. J Cell Physiol 1998;177:299-312.
64. Stallcup WB, Dahlin K, Healy P. Interaction of the NG2 chondroitin sulfate proteoglycan with type VI collagen. J Cell Biol 1990;111:3177-88.
65. Ohyama S, Harada T, Chikanishi T, Miura Y, Hasumi K. Nonlysine-analog plasminogen modulators promote autoproteolytic generation of plasmin(ogen) fragments with angiostatin-like activity. Eur J Biochem 2004;271:809-20.
66. Chatellier J, Buckle AM, Fersht AR. GroEL recognises sequential and non-sequential linear structural motifs compatible with extended beta-strands and α-helices. J Mol Biol 1999;292:163-72.
67. Argos P. A sensitive procedure to compare amino acid sequences. J Mol Biol 1987;193:385-96.
68. Argos P, Hanei M, Garavito RM. The Chou-Fasman secondary structure prediction method with an extended data base. FEBS Lett 1978;93:19-24.
69. Wilson CL, Hubbard SJ, Doig AJ. A critical assessment of the secondary structure α-helices and their termini in proteins. Protein Eng 2002;15:545-54.
70. Rost B, Yachdav G, Liu J. The PredictProtein server. Nucleic Acids Res 2004;32:W321-26.
71. Hubbard SJ, Eisenmenger F, Thornton JM. Modeling studies of the change in conformation required for cleavage of limited proteolytic sites. Protein Sci 1994;3:757-68.
72. de Pereda JM, Leynadier D, Evangelio JA, Chacon P, Andreu JM. Tubulin secondary structure analysis, limited proteolysis sites, and homology to FtsZ. Biochemistry 1996;35:14203-15.
73. Hayashi Y, Katada J, Sato Y, Igarashi K, Takiguchi Y, Harada T, Muramatsu M, Yasuda E, Uno I. Discovery and structure-activity relationship studies of a novel and specific peptide motif, Pro-X-X-X-Asp-X, as a platelet fibrinogen receptor antagonist. Bioorg Med Chem 1998;6:355-64.
74. Katada J, Hayashi Y, Sato Y, Muramatsu M, Takiguchi Y, Harada T, Fujiyoshi T, Uno I. A novel peptide motif for platelet fibrinogen receptor recognition. J Biol Chem 1997;272:7720-6.
75. Tandon NN, Holland EA, Kralisz U, Kleinman HK, Robey FA, Jamieson GA. Interaction of human platelets with laminin and identification of the 67 kDa laminin receptor on platelets. Biochem J 1991;274(Pt2):535-42.
76. Halatsch M-E, Hirsch-Ernst KI, Kahl GF, Weinel RJ. Increased expression of a6-integrin receptors and of mRNA encoding the putative 37 kDa laminin receptor precursor in pancreatic carcinoma. Cancer Lett 1997;118:7-11.
77. Maulik N. Redox signaling of angiogenesis. Antioxid Redox Signal 2002;4:805-15.
78. Maulik N. Redox regulation of vascular angiogenesis. Antioxid Redox Signal 2002;4:783-4.
79. Welsh SJ, Bellamy WT, Briehl MM, Powis G. The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1α protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Res 2002;62:5089-95.
80. Giannopoulou E, Papadimitriou E. Amifostine has antiangiogenic properties in vitro by changing the redox status of human endothelial cells. Free Radic Res 2003;37:1191-9.
81. Agarwal A, Munoz-Najar U, Klueh U, Shih SC, Claffey KP. N-acetyl-cysteine promotes angiostatin production and vascular collapse in an orthotopic model of breast cancer. Am J Pathol 2004;164:1683-96.
82. Welsh SJ, Powis G. Hypoxia inducible factor as a cancer drug target. Curr Cancer Drug Targets 2003;3:391-405.
83. Goldman Y, Peled A, Shinitzky M. Effective elimination of lung metastases induced by tumor cells treated with hydrostatic pressure and N-acetyl-L-cysteine. Cancer Res 2000;60:350-8.
84. Tozawa K, Okamoto T, Hayashi Y, Sasaki S, Kawai N, Kohri K. N-acetyl-L-cysteine enhances chemotherapeutic effect on prostate cancer cells. Urol Res 2002;30:53-8.
85. Albini A, Morini M, D'Agostini F, Ferrari N, Campelli F, Arena G, Noonan DM, Pesce C, De Flora S. Inhibition of angiogenesis-driven Kaposi's sarcoma tumor growth in nude mice by oral N-acetylcysteine. Cancer Res 2001;61:8171-8.
86. Zhao ZC, Zheng SS, Cheng WL, Wang X, Qi Y. Suppressing progress of pancreatitis through selective inhibition of NF-κB activation by using NAC. J Zhejiang Univ Sci 2004;5:477-82.